6533b7cffe1ef96bd1258477

RESEARCH PRODUCT

Differential in vitro Anti-HIV Activity of Natural Lignans

Prem S. SarinSusanne TrummHeinz C. SchröderEckart EichHelmut MerzRenate SteffenJutta SchulzWerner E.g. Müller

subject

Antiviral AgentsLigninLignansGeneral Biochemistry Genetics and Molecular BiologyCell LineMiceStructure-Activity RelationshipViral Proteinschemistry.chemical_compoundAnimalsHumansLeukemia L5178Lignanchemistry.chemical_classificationbiologyTopoisomeraseHIVvirus diseasesDNA topoisomerase II activityMolecular biologyReverse transcriptaseIn vitroDNA Topoisomerases Type IIEnzymechemistryViral replicationCell cultureHIV-1biology.proteinCell DivisionPlasmids

description

Abstract Two naturally occurring lignanolides, isolated from the tropical climbing shrub Ipomoea cairica, (-)-arctigen in and (-)-trachelogen in , were found to inhibit strongly replication of human immunodeficiency virus type 1 (HIV-1; strain HTLV-III B) in vitro. At a concentration of 0.5 (μм , (-)-arctigenin and (-)-trachelogenin inhibited the expression of HIV-1 proteins p 17 and p24 by 80 -90 % and 60 -70 % , respectively. The reverse transcriptase activity in the cul­ture fluids was reduced by 80 -90 % when the cells (HTLV-III B/H 9) were cultivated in the presence of 0.5 μм (-)-arctigen in or 1 μм (-)-trachelogenin . At the same concentrations, the formation of syncytia in the HTLV-III B/H 9-Jurkat cell system was inhibited by the compounds by more than 80%. A series of other lignan type compounds displayed no anti-HIV activity. Studying the molecular mechanism of action of (-)-arctigenin and (-)-trachelogenin we found that both compounds are efficient inhibitors of the nuclear matrix-associated DNA topoisomerase II activity, particularly of the enzyme from HIV -1-infected cells. Our results suggest that both compounds prevent the increase of topoisomerase II activity, involved in virus replication, after infection of cells with HIV -1.

https://doi.org/10.1515/znc-1990-11-1222